Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 337, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2019.577080
Keywords
Myasthenia gravis; Acetylcholine receptors; Neuromuscular junction; Steroids; Immunosuppressant drugs; Rituximab; Eculizumab
Categories
Funding
- Portuguese Science and Technology Foundation (FCT/MCT)
- European Funds (PRODER/COMPETE) [M-ERA-NET/0004/2015, UID/AGR/04033/2019]
- FEDER, under the Partnership Agreement PT2020
Ask authors/readers for more resources
Myasthenia Gravis (MG) - an autoimmune neuromuscular disease - is known by the production of auto-antibodies against components of the neuromuscular junction mainly to the acetylcholine receptor, which cause the destruction and compromises the synaptic transmission. This disease is characterized by fluctuating and fatigable muscle weakness, becoming more intensive with activity, but with an improvement under resting. There are many therapeutic strategies used to alleviate MG symptoms, either by improving the transmission of the nerve impulse or by ameliorating autoimmune reactions with e.g. steroids, immunosuppressant drugs, or monoclonal antibodies (rituximab and eculizumab). Many breakthroughs in the discovery of new therapeutic targets have been reported, but MG remains to be a chronic disease where the symptoms are kept in the majority of patients. In this review, we discuss the different therapeutic strategies that have been used over the years to alleviate MG symptoms, as well as innovative therapeutic approaches currently under study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available